Reader Request: Add FierceVaccines to your safe senders list

Thanks to your support, FierceVaccines' audience is larger and more active than ever before. In order to meet the growing needs of our readers, we're upgrading our Fierce e-mail newsletter delivery system starting next week.

To ensure uninterrupted FierceVaccines service, I'm asking all readers to take one minute and update the following e-mail setting:

  • Add [email protected] to your safe-senders list. As in the past, every issue of FierceVaccines will arrive from that e-mail address.

  • If your e-mail client or IT department requires an IP address to include on a whitelist, use 208.95.132.73. Please note that this IP address has changed, so if you have whitelisted us previously, an update is required.

We've created a helpful guide to show you how to change either option in a variety of e-mail clients, such as Outlook and Gmail. Click here to view instructions.

If for any reason you stop receiving our newsletters, please contact your IT administrator or e-mail us at [email protected]

- Arsalan Arif, Publisher (twitter | e-mail)

Suggested Articles

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.